loader image
01
Effective
Prescription
Mental Wellness.
For Everyone.
Tactogen is a public benefit company developing a next generation of mental wellness medicines. 

Our goal is to make transformative medicines that are safer, more effective, and more accessible.
02
OUR VISION
AND VALUES
Our vision is a world where novel medicines and treatments dramatically reduce or even eliminate barriers to effective care. Where community wellness is the bedrock of the healthcare system. And where everyone has the tools and support to meet life's challenges.
03
Founders
MATTHEW BAGGOTT, PHD
Co-founder & CeO
Matthew is a neuroscientist with a three-decade-plus career that includes data science, preclinical pharmacology, genomics, clinical trials, and drug development. Matthew started his career in the first lab to study the long-term effects of MDMA on the brain. He next moved to a psychopharmacology lab at UCSF that focused on clinical trials for substance use disorder pharmacotherapies. Matthew later consulted with MAPS, drafting regulatory documents to help them gain FDA permission to start Phase 2 trials with MDMA. Other career highlights include work to develop the formulation for Suboxone, conducting the first federally funded clinical studies of MDMA, and conducting the first modern clinical study of the related compound MDA. Before starting Tactogen, Matthew was a Director of Data Science and Engineering at Genentech (the company that started the biotech industry, now a subsidiary of Hoffmann-La Roche).
LUKE PUSTEJOVSKY
Co-founder & COO
Luke is an operations executive with over fifteen years of experience leading mental health, neurotech and climate tech companies. He started Tactogen to help commercialize affordable medicines that can improve lives. Before co-founding Tactogen, Luke was COO of Delta Separations (acquired by Gibraltar Industries) and CEO of Curian. Prior to focusing on mental health and neuro-related innovations, he concentrated on climate tech. Luke was Director of Business Development at View, and Director of Sales and Marketing at Calera, both backed by Khosla Ventures. He worked as an Analyst and Associate at Boston-based Echelon Ventures and Saturn Capital. Luke concentrates on fundraising and grants, cash flow, corp dev/partnerships, marketing, ops, team building, and culture.
04
OUR PIPELINE
Developing IP That Provides Unique Value to Patients
Tactogen is a mission-based and research-driven pharmatech company that uses machine learning and targeted assays to identify promising medicines and new treatments. We seek to understand and leverage the ability of novel small molecules to improve health in a variety of contexts, including anxiety, depression, and stress-related disorders.
05
NEWS
November 28, 2023
TACTOGEN'S CEO MATTHEW BAGGOTT FEATURED ON HAMILTON MORRIS PODCAST
Hamilton Morris released his podcast interview with Matthew Baggott.

November 23, 2023
PSYCHEDELIC SCIENCE '23 TALK AVAILABLE FOR REPLAY
Matthew Baggott's talk, "Beyond Ecstasy: Progress in Developing and Understanding a Novel Class of Therapeutic Medicine" from Psychedelic Science 2023 is now available for replay.
September 26, 2023
TACTOGEN ANNOUNCES GRANT OF U.S. PATENT COVERING MDMA ANALOGS
Tactogen announced today that the United States Patent and Trademark Office has granted U.S. patent 11767305, covering composition of matter for novel MDMA derivatives useful for the improvement of mental health. This patent represents the first U.S. patent awarded for novel psychoactive MDMA derivatives.
06
CONNECT











      © Copyright by Tactogen 2022
      crossmenuchevron-down